Introduction: Legal Services for Life Sciences Companies
This page covers the services, expertise, and unique value of Faison Law Group as a life sciences law firm, specifically designed for founders, executives, and investors in biotech, pharma, and digital health. Legal strategy is critical for innovation-driven life sciences companies facing complex regulatory and business challenges. Whether you are launching a new biotech startup, scaling a digital health platform, or investing in pharmaceutical innovation, the right legal counsel can make the difference between success and costly setbacks.
A life sciences law firm provides specialized legal counsel for biotech, pharma, and medical device industries, guiding innovations from R&D to market. Life sciences law involves unique legal disciplines such as regulatory compliance, intellectual property, and corporate law. Life sciences lawyers serve a diverse range of clients including pharmaceutical, biotechnology, and medical device companies. This page is your resource for understanding the legal services available to life sciences companies and how Faison Law Group can help you navigate this complex landscape.
What Is a Life Sciences Law Firm? (Definition & Scope)
A life sciences law firm is a specialized legal practice that provides counsel to companies in the biotechnology, pharmaceutical, medical device, diagnostics, and digital health sectors. These firms guide innovations from research and development through clinical trials, regulatory approval, commercialization, and beyond. Life sciences law encompasses regulatory compliance (such as FDA, HIPAA, and international standards), intellectual property (patents, licensing, and trade secrets), and corporate law (formation, financing, M&A, and governance). Life sciences lawyers often have industry experience and serve a diverse range of clients, including startups, established companies, investors, and research institutions.
Summary: What Does a Life Sciences Law Firm Do?
A life sciences law firm provides specialized legal counsel for biotech, pharma, and medical device industries, guiding innovations from R&D to market. Life sciences law involves unique legal disciplines such as regulatory compliance, intellectual property, and corporate law. Life sciences lawyers serve a diverse range of clients including pharmaceutical, biotechnology, and medical device companies. Life sciences law firms offer holistic support across a product’s entire lifecycle, including clinical trials, data privacy, and regulatory matters. They manage compliance with regulatory pathways for product approval, including NDA/ANDA/BLA submissions, and often include professionals with industry experience.
Life Sciences Counsel for Innovation-Driven Companies
Faison Law Group is a boutique transactional life sciences law firm based in Millersville, Maryland, serving clients nationally with concentrated experience in New York City, Boston, San Francisco, Southern California (including Los Angeles and San Diego), Maryland, Washington, DC, Northern Virginia, Austin, Philadelphia, and South Florida. The firm focuses on finance, startup and venture formation, mergers and acquisitions, AI privacy, and complex corporate transactions for biotechnology, pharmaceutical, medical device, diagnostics, digital health, and platform technology companies.
Faison Law Group has significant experience at the intersection of healthcare life sciences, providing legal, regulatory, and strategic advisory services to companies operating within these rapidly evolving sectors. The life sciences industry is characterized by rapid evolution and regulatory complexity, requiring companies to stay ahead of shifting legal and business landscapes. Life sciences companies face an increasingly complex and competitive landscape and often require tailored solutions to address their unique challenges.
The life sciences practice is especially suited to early-stage and growth-stage life sciences companies—from pre-seed through Series B—and the investors, funds, and strategic partners who work with them. This is not a mass tort or product liability practice. Instead, Faison Law Group concentrates on the transactional, governance, and regulatory compliance issues that define how life sciences companies form, finance, collaborate, and exit.
This page provides general, educational information about life sciences legal issues and does not constitute legal or investment advice. Nothing here is an offer or solicitation to buy or sell securities. All outcomes depend on specific facts, regulatory interpretation, and market conditions. Companies and investors should consult qualified counsel before making decisions.
Ready to discuss your life sciences legal needs? Call Faison Law Group at (667) 213-6640 or message us online to schedule a consultation.
Who We Serve
- Biotech companies developing therapeutics, biologics, and cell and gene therapies
- Medical device developers and diagnostics platforms from concept through commercialization
- Digital health and AI-driven healthcare technology ventures
- Pharmaceutical company spin-outs and university-affiliated startups
- Emerging venture capital funds and private equity firms investing in life sciences
- Healthcare companies pursuing acquisitions, divestitures, or strategic partnerships
What Makes This Practice Different
- Recognized for excellence in life sciences legal services
- Boutique size with direct partner involvement on every matter
- Operates as a private practice, providing independent, specialized legal counsel to healthcare life sciences and related companies
- Deep understanding of venture capital dynamics and securities laws
- Extensive experience in M&A and complex corporate transactions
- Practical AI privacy and data governance counsel for modern life sciences platforms
- Good life sciences law firms align their legal strategies with clients’ business objectives, maximizing the value of intellectual property
- Fixed-fee and predictable billing arrangements where appropriate
- National footprint covering major U.S. life sciences and innovation hubs
Integrated Life Sciences, Venture, and Regulatory Capabilities
Life sciences companies rarely face isolated legal issues. A biotech startup preparing for a Series A round must simultaneously address intellectual property ownership, regulatory risk disclosures, board governance, and investor rights. A digital therapeutics company negotiating a strategic alliance needs to consider how the deal affects future fundraising, exit options, and data privacy obligations.
Faison Law Group combines experience in life sciences transactions, securities compliance, fund formation, and AI privacy to provide an integrated perspective on risk and growth. Rather than treating each legal workstream as separate, the firm helps clients see how decisions in one area affect outcomes in others.
Typical Client Scenarios
- A Boston synthetic biology startup closing a seed round, needing cap table cleanup, IP assignment, and securities compliance
- A New York digital therapeutics company structuring a strategic partnership with a larger pharmaceutical industry player
- A Bay Area diagnostics platform preparing for acquisition, requiring IP diligence, regulatory status review, and transition planning
- An Austin-based AI health analytics company addressing HIPAA compliance and cross-border data transfer issues
The firm does not guarantee any regulatory outcome or fundraising result. Instead, it focuses on helping clients understand their options and navigate complex decision points with clear legal analysis.
Coordination With Specialized Advisors
- When matters require niche patent prosecution or FDA regulatory expertise, Faison Law Group coordinates with specialized counsel
- Tax structuring, international clinical trial issues, or complex accounting matters are handled through trusted advisor networks
- The firm acts as transactional quarterback, ensuring all workstreams align with the client’s strategic goals
With this integrated approach, we address the full spectrum of legal needs for life sciences companies, as detailed in our core practice areas below.
Core Life Sciences Practice Areas
This section provides a practical overview of the main categories of work Faison Law Group handles for life sciences clients. Life sciences companies face significant challenges related to product development and commercialization, requiring legal counsel with deep industry knowledge. Intellectual property expertise is crucial for life sciences firms, especially in patent prosecution, licensing, strategy, and portfolio management. Faison Law Group provides tailored legal solutions to help clients protect and enhance their value in a competitive marketplace. Life sciences legal services include guidance on complex transactional, regulatory, and compliance matters, and often involve structuring complex cross-border transactions and strategic partnerships.
The firm’s work concentrates in five pillars:
| Practice Pillar | Focus Areas |
|---|---|
| Startup and Venture Formation | Entity choice, founder agreements, equity allocation, governance |
| Venture and Growth Financings | SAFEs, convertible notes, priced rounds, securities compliance |
| Strategic Collaborations and Licensing | License agreements, co-development deals, professional services agreements |
| M&A and Corporate Transactions | Buy-side and sell-side transactions, earn-outs, regulatory diligence |
| AI, Data, and Privacy | HIPAA compliance, data governance, AI model training protocols |
In addition, Faison Law Group has significant experience advising life sciences companies on public offerings, including equity and debt offerings, securities exchange listings, and regulatory compliance for companies seeking to raise capital through public markets.
All descriptions below are illustrative. Outcomes depend heavily on specific facts, regulatory interpretation, and market conditions. Nothing in these summaries should be read as a promise of success in any particular matter.
Startup and Venture Formation
Startup Formation, Governance, and Early-Stage Structuring
Many life sciences start-ups and ventures in New York, Boston, and San Francisco spin out from academic medical centers, research universities, or corporate R&D programs. These companies need careful structuring from day one to avoid governance and cap table issues that complicate later fundraising or exits.
Key Formation Issues:
- Entity Choice: Deciding between a Delaware C-corporation and an LLC involves trade-offs around tax treatment, investor preferences, and regulatory considerations. Most venture capital funds and strategic investors prefer C-corps for their familiarity with preferred stock structures.
- Founder and Advisor Equity: Allocating equity among scientific founders, co-founders, and early advisors requires attention to vesting schedules, repurchase rights, and cliff provisions.
- IP Assignment: Ensuring all intellectual property created by founders, consultants, and employees is properly assigned to the company—before investors conduct diligence—is critical.
- University and Hospital Relationships: Many life sciences startups maintain lab access, sponsored research agreements, or licensing relationships with academic institutions. These arrangements must be structured to preserve freedom to operate and avoid conflicts.
Faison Law Group’s experience with venture ecosystems helps founders avoid corporate governance terms that can later create friction with institutional investors. Entity choice and cap table decisions carry tax, regulatory, and financing consequences, and should be discussed with qualified legal and tax advisers.
Life sciences attorneys should have prior research or industry experience to provide sophisticated legal advice. Many life sciences attorneys also have advanced degrees in scientific fields such as biology, chemistry, and engineering.
Venture and Growth Financings
Venture Financings and Securities Compliance for Life Sciences
Life sciences startups typically follow a financing path from pre-seed and seed rounds—often using SAFEs or convertible notes—through priced preferred stock rounds such as Series A or Series B. Each stage involves securities laws compliance obligations that founders often underestimate.
Financing Structures:
- SAFEs: Simple Agreements for Future Equity, developed by Y Combinator, are common at early stages. Recent bankruptcy court decisions have treated SAFEs as equity-like instruments, which affects creditor priority in distressed situations.
- Convertible Notes: These provide debt-like features including maturity dates and interest, offering different risk profiles for founders and investors.
- Priced Rounds: Series A and later rounds involve detailed negotiation of preferred stock terms, including liquidation preferences, anti-dilution provisions, board seats, and information rights.
Faison Law Group advises companies, founders, and occasionally emerging venture capital funds on structuring these financings in compliance with U.S. federal and state securities laws. Common exemptions include Regulation D (Rules 506(b) and 506(c)), and where appropriate, Regulation CF or Regulation A.
Life Sciences-Specific Financing Issues:
- Data rights and ownership representations in investor diligence
- Clinical trial and regulatory risk disclosures tied to trial phases or FDA submissions
- Milestone-based financing tranches linked to scientific or regulatory achievements
- Cap table management for companies with multiple founders and early investors
The firm provides legal and regulatory guidance on these matters but does not give investment advice or recommend particular securities or exemptions as suitable for any specific issuer or investor. Securities regulation is complex and fact-specific, and companies should consult counsel before relying on any exemption or conducting an offering.
Preparing for a Series A? Call (667) 213-6640 or message us online to discuss how to prepare your cap table, governance documents, and disclosure framework.
Strategic Collaborations and Licensing
Strategic Collaborations, Licensing, and Commercial Agreements
Collaborations and licensing agreements are central to life sciences business models. Many companies depend on third-party intellectual property, manufacturing capabilities, distribution networks, or clinical data to advance their programs.
Common Agreement Types:
| Agreement Type | Typical Use Case |
|---|---|
| License Agreements | Access to platform technologies, biologics, or proprietary data |
| Sponsored Research Agreements | Funding academic research with IP rights flowing to sponsor |
| Co-Development Deals | Shared investment in drug discovery or device development |
| Supply and Manufacturing Contracts | Third-party production of biologics, devices, or components |
| Distribution Agreements | Commercialization rights in specific territories or therapeutic areas |
Key Negotiation Points:
- Field of use limitations and therapeutic area restrictions
- Territory exclusivity and sub-licensing rights
- Milestone payment structures tied to development achievements
- Royalty terms and accounting provisions
- Improvement IP ownership and prosecution rights
- Publication rights in academic clinical trial agreements
Faison Law Group focuses on aligning contractual rights with long-term fundraising and exit strategy. Future investors and acquirers need to see clear, reliable chains of rights before committing capital. The firm often coordinates with scientific and regulatory teams to ensure contract terms reflect realistic development and approval timelines.
Strategic alliances in the life sciences space require careful attention to how deal terms affect capital raising and M&A positioning. Joint ventures, professional services agreements, and clinical trial agreements all benefit from transactional counsel who understands industry dynamics and the priorities of strategic investors.
With these core practice areas, Faison Law Group supports clients through every stage of the product and business lifecycle, from formation to exit.
M&A and Corporate Transactions
Mergers, Acquisitions, and Corporate Transactions
Faison Law Group regularly advises on sell-side and buy-side transactions involving life sciences and health technology companies. The firm focuses on identifying risk, structuring appropriate protections, and helping clients make informed decisions about capital markets transactions.
Core M&A Tasks:
- Letter of Intent Negotiation: Structuring exclusivity, due diligence timelines, and key deal terms
- Due Diligence: Reviewing IP ownership, regulatory compliance status, clinical and quality records, and licensing arrangements
- Purchase Agreement Drafting: Allocating risk through representations, warranties, indemnities, and escrow structures
- Earn-Out Structuring: Tying post-closing payments to revenue, regulatory milestones, or other performance metrics
The firm does not guarantee that any deal will close or that lenders or regulators will approve a transaction. The goal is to identify risk, structure appropriate protections, and help clients make informed decisions about capital markets transactions.
AI, Data, and Privacy
AI, Data, and Privacy in Life Sciences
Many current life sciences ventures involve AI-driven diagnostics, predictive analytics, personalized medicine platforms, or digital therapeutics. These businesses often operate across multiple jurisdictions with complex privacy and data-sharing rules.
Common AI and Data Issues:
- HIPAA Compliance: Protected health information requires administrative, technical, and physical safeguards, along with appropriate business associate agreements
- De-Identification Protocols: Using clinical or genomic datasets for AI model training requires careful attention to re-identification risk
- Cross-Border Data Transfers: Multi-site clinical trials and international research collaborations involve data transfer frameworks and regulatory approvals
- AI Governance: Internal policies for model validation, bias testing, and regulatory documentation
Faison Law Group’s AI privacy and technology experience helps life sciences clients structure data use agreements, consent frameworks, and internal governance policies that support drug discovery and clinical innovation while mitigating regulatory and contractual risk.
Evolving Compliance Expectations:
Compliance expectations around AI in healthcare continue to change. Companies should treat data governance and AI risk management as ongoing programs rather than one-time checklists. Recent FDA guidance on Software as a Medical Device (SaMD) adds regulatory overlay to AI-driven diagnostics and decision support tools.
The firm does not suggest that any AI or privacy structure will eliminate risk. Instead, the focus is on reasoned, risk-aware design aligned with evolving law and guidance.
Have questions about AI, data privacy, or HIPAA compliance for your life sciences platform? Message us online to schedule a consultation.
Representative Life Sciences Client Profiles and Matters
Faison Law Group represents a broad range of life sciences market participants: early-stage biotech companies and medical device developers, digital health platforms, diagnostics labs, small to mid-size healthcare businesses, and emerging private equity funds and venture capital funds investing in the sector.
The following anonymized scenarios illustrate the types of matters the firm handles:
- Represented a San Francisco–based biotechnology company developing a pipeline of in vivo cell therapies for the treatment of cancer and inherited blood disorders in a multi-million dollar asset sale.
- Advised an early-stage life sciences venture fund focused on investments in biotechnology, therapeutics, and healthcare innovation on formation, regulatory structuring, and early-stage investment transactions.
- Represented an AI-powered quality control and quality assurance analytics company built for biomanufacturing, focused on automating and standardizing QC/QA across complex biological assays, including organoids, 3D tissues, and high-value bioproduct workflows, in its seed-stage fundraising.
- Represented a university spin-out and National Science Foundation grant awardee focused on converting agricultural biomass into high-performance cellulose nanofibers with environmental and commercial applications in its formation and licensing of university intellectual property.
Past engagements do not predict or guarantee future results. Success in any matter depends on numerous factors, including business conditions, regulatory interpretation, and market dynamics.
Geographic Focus: Major Life Sciences and Innovation Hubs
While Faison Law Group is based in Millersville, Maryland, the firm regularly advises clients operating in or expanding into major U.S. life sciences and technology hubs.
Key Geographies:
| Region | Life Sciences Activity |
|---|---|
| Boston | Established biotech and pharmaceutical cluster; home to industry leaders in therapeutics, gene therapy, and drug pricing innovation |
| New York City | Growing digital health ecosystem; public company clients in healthcare and tech companies in AI diagnostics |
| San Francisco / Bay Area | Venture-backed life sciences and AI companies; strong venture capital and private equity fund presence |
| Southern California (Los Angeles and San Diego) | Expanding life sciences ecosystem with growing biotech, medical device, and digital health activity |
| Austin | Emerging life sciences space with growing medical device and digital health activity |
| South Florida | Healthcare services consolidation; diagnostics and clinical practice M&A |
| Maryland, Washington DC, Northern Virginia | Research institutions, federal health agencies, digital health platforms, and government contracting |
| Philadelphia | Pharmaceutical industry presence; academic medical centers and university spin-outs |
The firm works remotely with distributed teams and investors, coordinating across time zones and collaborating with other advisors as needed. Whether your company is based in a traditional biotech cluster or an emerging innovation market, Faison Law Group can provide strategic counsel on your life sciences transactions.
Why Life Sciences Companies Choose Faison Law Group
A lean, focused transactional firm can be a strong fit for innovation-driven life sciences businesses that need senior attention at sustainable fee levels.
Key Differentiators:
- Boutique Size, Partner Involvement: Every matter receives direct attention from experienced counsel, not a pyramid of associates learning on your project
- Deep Industry Knowledge: The firm combines life sciences transaction experience with securities compliance, fund formation, and AI privacy capabilities
- Venture and M&A Experience: Extensive experience with early-stage financings, strategic collaborations, and buy-side and sell-side M&A across tech companies and healthcare companies
- Predictable Pricing: Fixed-fee and flat-rate billing arrangements where appropriate, helping clients manage legal budgets during capital-constrained growth phases
- Long-Term Relationships: Supporting clients from formation documents and initial financings through later strategic transactions, acquisitions, or liquidity events
The firm represents a spectrum of organizations—from large, publicly traded multinationals needing targeted transactional support to small, founder-led businesses building their first regulated products. The role is to provide legal analysis, risk assessment, and transactional execution. Clients trust the firm to help them understand options, not to make business or investment decisions on their behalf.
How We Work With Founders, Executives, and Investors
Faison Law Group takes a collaborative approach, working closely with scientific founders, C-suite executives, boards, and investors to align legal strategy with product roadmaps, regulatory matters, and capital planning. The firm also has significant experience advising on executive compensation matters for life sciences companies, ensuring compliance and effective incentive structures.
Outsourced General Counsel Model
Many early-stage life sciences clients do not yet have in house counsel. The firm often acts as outsourced or fractional general counsel, helping companies prioritize issues and allocate limited resources. This includes:
- Preparing board materials and governance documentation
- Managing diligence requests from investors and strategic partners
- Reviewing and negotiating licensing agreements and professional services agreements
- Advising on regulatory compliance issues affecting product development
- Coordinating with specialized FDA regulatory or patent prosecution counsel
Practical, Action-Oriented Communication
Communications are designed to translate regulatory and transactional complexity into clear choices and trade-offs. The team advises on legal risks and options while respecting that management and investors make final strategic decisions.
Coordination With Other Advisors
When matters require niche expertise—such as specialized patent prosecution or international clinical trial regulatory issues—the firm partners with other advisors and coordinates efforts to avoid gaps or duplication. Whether working with patent prosecution specialists, tax counsel, or FDA consultants, the goal is integrated support for the client’s transaction or program.
Engage Faison Law Group for Your Life Sciences Legal Needs
Whether you’re a founder preparing for an upcoming financing, an executive negotiating a licensing deal, or an investor conducting diligence on a potential portfolio company, early legal strategy matters.
Common Reasons to Reach Out:
- Preparing for a Series A or Series B financing
- Structuring a strategic collaboration or co-development agreement
- Addressing AI and data privacy questions for digital health platforms
- Organizing corporate governance ahead of board or investor review
- Preparing for an acquisition, divestiture, or exit transaction
- Navigating regulatory issues affecting product development or commercialization
The content on this page is for informational purposes only and does not constitute legal or investment advice. Reading this page does not create an attorney-client relationship. Decisions regarding securities offerings, regulatory strategy, and business transactions should be made in consultation with qualified counsel who understand the specific facts of your situation.
Ready to discuss your life sciences transaction?
Call Faison Law Group at (667) 213-6640 to schedule a consultation.
Prefer to connect online? Message us here and request a focused strategy session—we respond quickly and work around busy founder and executive schedules.
If your life sciences company is planning a Series A round, call (667) 213-6640 to discuss how to prepare your cap table, governance, and disclosures.
For confidential discussion about an upcoming acquisition or licensing deal, contact us online and request a strategy session with our team.
Faison Law Group serves life sciences clients in New York City, Boston, San Francisco, Southern California (including Los Angeles and San Diego), Maryland, Washington, DC, Northern Virginia, Austin, Philadelphia, and South Florida. Connect with us before you sign term sheets or transaction documents.